Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pancreatic Cancer
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 271
- Locations
- 1
- Primary Endpoint
- We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
Detailed Description
This research is being done to identify which pancreatic cancer patients should undergo genetic evaluation. A patient's personal and family history of cancer is the information typically used to make this decision, but there are currently no accurate, evidence-based guidelines that exist to help doctors use this information to make a decision. The investigators hope that by testing all new pancreatic cancer patients, they can determine which clinical factors predict for genetic mutations in order to create a risk assessment tool. The investigators want to determine which patients with pancreatic cancer will benefit from genetic testing. To do so, the investigators will offer all patients with pancreatic cancer in the Dana-Farber Gastrointestinal Oncology clinic referral for genetic evaluation. At the Cancer Genetics and Prevention clinic appointment, the provider will review the patient's personal and familial history of cancer and offer genetic testing.
Investigators
Matthew B. Yurgelun, MD
Matthew B. Yurgelun, MD
Dana-Farber Cancer Institute
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of pancreatic ductal adenocarcinoma
- •Signed initial informed consent
- •Participant agrees to genetic counseling
Exclusion Criteria
- •Prospective participant unable to sign informed consent based on referring physician recommendation.
- •Patient has neuroendocrine pancreatic tumor
Outcomes
Primary Outcomes
We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool
Time Frame: Up to 5 years
Secondary Outcomes
- Evaluate Patient Experience With Genetic Testing(up to 5 years)
- Summarize patient satisfaction with Genetic counseling(up to 5 years)
- Number of patients who disclose genetic testing results to relatives(up to 5 years)